| Revision as of 19:32, 31 December 2016 editOceanflynn (talk | contribs)Autopatrolled, Extended confirmed users55,181 edits inline edit inline citation← Previous edit | Revision as of 20:57, 31 December 2016 edit undoOceanflynn (talk | contribs)Autopatrolled, Extended confirmed users55,181 edits duplicationNext edit → | ||
| Line 1: | Line 1: | ||
| '''Nusinersen''' (formerly, IONIS-SMN<sub>Rx</sub>, ISIS-SMN<sub>Rx</sub>), marketed as Spinraza,<ref>{{cite web|url=http://smanewstoday.com/2016/11/01/regulatory-applications-sma-therapy-nusinersen-accepted-us-fda-eu-ema |title=Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU |publisher=BioNews Services, LLC|date= |accessdate=2016-11-15}}</ref> is the first drug approved by the U.S. ] for use in treating ]. Nusinersen is a proprietary ] that modulates ] of the '']'' gene, functionally converting it into '']'' gene. It was developed by ] and licensed to ], with initial financial support from SMA Foundation and Cure SMA. | '''Nusinersen''' (formerly, IONIS-SMN<sub>Rx</sub>, ISIS-SMN<sub>Rx</sub>), marketed as Spinraza,<ref>{{cite web|url=http://smanewstoday.com/2016/11/01/regulatory-applications-sma-therapy-nusinersen-accepted-us-fda-eu-ema |title=Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU |publisher=BioNews Services, LLC|date= |accessdate=2016-11-15}}</ref> is the first drug approved by the U.S. ] for use in treating ] (SMA), a rare pediatric disease. Nusinersen is a proprietary ] that modulates ] of the '']'' gene, functionally converting it into '']'' gene. It was developed by ] and licensed to ] for a $75 million license fee,<ref name="genengnews_2016">{{citation |url=http://www.genengnews.com/gen-news-highlights/biogen-shells-out-75m-to-develop-ionis-nusinersen-after-positive-phase-iii-results/81253027 |date=August 1, 2016 |title=Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results |accessdate=December 31, 2016}}</ref> with initial financial support from SMA Foundation and Cure SMA. | ||
| == Status == | == Status == | ||
| Line 6: | Line 6: | ||
| Nusinersen has ] designation in the ] and the ].<ref>{{cite web|url=http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6236 |title=nusinersen |publisher=NHS New Drugs Online Database |date= |accessdate=2016-05-14}}</ref> | Nusinersen has ] designation in the ] and the ].<ref>{{cite web|url=http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=6236 |title=nusinersen |publisher=NHS New Drugs Online Database |date= |accessdate=2016-05-14}}</ref> | ||
| ] paid a $75 million license fee to ] in August 2016, "after exercising its option to develop and commercialize nusinersen globally"<ref name="genengnews_2016">{{citation |url=http://www.genengnews.com/gen-news-highlights/biogen-shells-out-75m-to-develop-ionis-nusinersen-after-positive-phase-iii-results/81253027 |date=August 1, 2016 |title=Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results |accessdate=December 31, 2016}}</ref> The drug was accepted as a FDA's ] drug because of a successful 2015 clinical trial involving 82 infants in which "40 percent of babies on the drug reached milestones such as sitting, crawling and walking."<ref name="NYT_Spinraza_Thomas">{{citation |url=http://www.nytimes.com/2016/12/30/business/spinraza-price.html |title=Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval |author=Katie Thomas |date=December 30, 2016 |publisher=''New York Times'' |accessdate=December 31, 2016}}</ref> According to the '']'', Spinraza, "will be among the most expensive drugs in the world", with an estimated cost $750,000 in the first year of treatment and "about $375,000 annually after that."<ref name="NYT_Spinraza_Thomas" /> Peak annual sales of nusinersen "could reach around $1.5 billion, triggering up to $150 million in additional milestone payments and a royalty percentage up to the mid-teens."<ref name="Biogen_Ionis">{{citation |url=http://www.fool.com/investing/2016/10/05/better-buy-anavex-life-sciences-corp-vs-ionis-phar.aspx |title=Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc. |author=Cory Renauer |date=October 5, 2016 |accessdate=December 31, 2016}}</ref> | |||
| == References == | == References == | ||
Revision as of 20:57, 31 December 2016
Nusinersen (formerly, IONIS-SMNRx, ISIS-SMNRx), marketed as Spinraza, is the first drug approved by the U.S. Food and Drug Administration for use in treating spinal muscular atrophy (SMA), a rare pediatric disease. Nusinersen is a proprietary antisense oligonucleotide that modulates alternate splicing of the SMN2 gene, functionally converting it into SMN1 gene. It was developed by Ionis Pharmaceuticals and licensed to Biogen for a $75 million license fee, with initial financial support from SMA Foundation and Cure SMA.
Status
The drug is approved for use in all types of spinal muscular atrophy regardless of age and disease stage. It is administered directly to the central nervous system using intrathecal injection once every 4 months.
Nusinersen has orphan drug designation in the United States and the European Union.
Biogen paid a $75 million license fee to Ionis Pharmaceuticals in August 2016, "after exercising its option to develop and commercialize nusinersen globally" The drug was accepted as a FDA's priority review drug because of a successful 2015 clinical trial involving 82 infants in which "40 percent of babies on the drug reached milestones such as sitting, crawling and walking." According to the New York Times, Spinraza, "will be among the most expensive drugs in the world", with an estimated cost $750,000 in the first year of treatment and "about $375,000 annually after that." Peak annual sales of nusinersen "could reach around $1.5 billion, triggering up to $150 million in additional milestone payments and a royalty percentage up to the mid-teens."
References
- "Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU". BioNews Services, LLC. Retrieved 2016-11-15.
- ^ Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results, August 1, 2016, retrieved December 31, 2016
- Grant, Charley (2016-12-27). "Surprise Drug Approval Is Holiday Gift for Biogen". Wall Street Journal. ISSN 0099-9660. Retrieved 2016-12-27.
- "nusinersen". NHS New Drugs Online Database. Retrieved 2016-05-14.
- ^ Katie Thomas (December 30, 2016), Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval, New York Times, retrieved December 31, 2016
{{citation}}: Italic or bold markup not allowed in:|publisher=(help) - Cory Renauer (October 5, 2016), Better Buy: Anavex Life Sciences Corp. vs. Ionis Pharmaceuticals, Inc., retrieved December 31, 2016
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |